GENE ONLINE|News &
Opinion
Blog

AstraZeneca J&J oncology
EGFR
EGFR Lung Cancer 2025: AstraZeneca’s Tagrisso vs J&J’s Rybrevant in Global Trials Highlight Efficacy and Tolerability Trade-Offs
2025-09-30
LATEST
40 Percent of Commercially Insured Individuals Affected by Copay Accumulator and Maximizer Programs in 2025
2026-04-15
Medicare Part D Enrollment Data for 2026 Shows 83% of Seniors in Plans with Preferred Pharmacy Networks
2026-04-15
Hybrid Hub Models on the Rise as 2026 Patient Services Report Highlights Technology Gaps and Interoperability Challenges
2026-04-15
Mark Cuban Comments on FTC Settlement with Express Scripts Amid 340B Program’s Role in Hospital Consolidations
2026-04-15
Pharmaceutical Experts Advocate for Flexible Hybrid Models to Replace One-Size-Fits-All DTP Programs
2026-04-15
Mark Cuban Keynotes Sold-Out Drug Channels Leadership Forum 2026 Featuring 340B Program Discussion
2026-04-15
Bansi Nagji Advocates for Precision and Personalized Care in Rare Disease Pharmacy Model
2026-04-15
READ MORE
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
2026-04-29
BIO Korea 2026 (R&D & Collaborations)
Seoul, South Korea
2026-05-11
ASGCT (Gene and Cell Therapy Advances)
Boston, Massachusetts
2026-05-29
ASCO 2026 (Major Oncology Clinical Data)
Chicago, Illinois
2026-06-22
BIO International Convention (Global Biotech Showcase)
Boston, Massachusetts
2026-06-25
Medical Taiwan 2026 (Devices, Diagnostics, Digital & Smart Health)
Taipei, Taiwan
SEE MORE
Scroll to Top